Prognostic factors and efficacy of different chemotherapeutic regimens in patients with mediastinal nonseminomatous germ cell tumors

Fedyanin, Mikhail; Tryakin, Alexey; Mosyakova, Yana; Bulanov, A.; Zakharova, T.; Polockii, B.; Garin, A.; Tjulandin, S.

doi:10.1007/s00432-013-1567-1

Cited by 12 publications

(9 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Primary malignant MGCT constitutes 10% of the total GCTs treated at our center and identical to the incidence of 3%‐15% in published literature 1,4,6,16,19,21‐29 . Diagnosis is sometimes difficult in comparison to their gonadal counterpart due to differential diagnosis of thymic neoplasm, lymphoma, sarcoma, and other mediastinal lesions.…”

Section: Discussionsupporting

confidence: 61%

“…Primary malignant MGCT constitutes 10% of the total GCTs treated at our center and identical to the incidence of 3%-15% in published literature. 1,4,6,16,19,[21][22][23][24][25][26][27][28][29] Diagnosis is sometimes difficult in comparison to their gonadal counterpart due to differential diagnosis of thymic neoplasm, lymphoma, sarcoma, and other mediastinal lesions. Mediastinal NSGCT is more aggressive in presentation with a high volume of disease in the majority of cases and superior vena cava obstruction may present in around 10% of cases but it was much higher (28%) in our series (Table 1) (Table 3).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Multimodality treatment outcome in patients with primary malignant mediastinal germ cell tumor in adults

Biswas

Dabkara

Sengupta³

et al. 2020

Cancer Reports

View full text Add to dashboard Cite

Background Malignant mediastinal germ cell tumor (MGCT) is rare and has poor outcomes even after multimodality treatment. Data from resource‐poor countries are scarce in the literature. Aims To evaluate the clinicopathologic features and treatment outcome of primary malignant MGCT at our center. Methods and Results Single institutional data review of patients aged ≥18 years, treated with a diagnosis of malignant MGCT between Nov'2013 and Nov'2019. Risk stratification was done as per International Germ Cell Cancer Collaborative Group (IGCCCG) classification. Patients were treated with platinum based chemotherapy and surgical resection for the residual disease was performed in non‐seminomatous histology.28 patients had MGCT with a median age of 25 years (range:18‐36) and all were male. Seven patients had superior vena cava obstruction (SVCO) at diagnosis and pre‐treatment histological diagnosis was available in 23 (82%) patients. Seven (25%) patients had seminoma histology, all were of good risk as per IGCCCG risk criteria, whereas others had non‐seminoma histology with poor‐risk group. Seven patients with seminoma histology achieved a complete response after initial treatment. Six patients with non‐seminoma histology underwent complete resection of residual disease post‐chemotherapy and five revealed residual viable tumors. After a median follow‐up of 10.8 months (range:2.9‐75), 3‐year progression‐free survival (PFS) and overall survival (OS) estimate was 61.2% and 94.7% in the whole cohort, respectively and 3‐year PFS and OS estimate was 100% in patients with seminoma histology. Conclusions This is the largest data set of MGCT patients' outcomes reported from India with multi‐modality treatment. All patients were male and one‐fourth had SVCO at presentation. Seminoma histology patients had a 100% outcome after initial platinum based chemotherapy. But, those with non‐seminoma histology had a poor outcome even with chemotherapy and surgery.

show abstract

Section: Discussionsupporting

confidence: 61%

Section: Discussionmentioning

confidence: 99%

Multimodality treatment outcome in patients with primary malignant mediastinal germ cell tumor in adults

Biswas

Dabkara

Sengupta³

et al. 2020

Cancer Reports

View full text Add to dashboard Cite

show abstract

“…To our knowledge, this was the fourth largest single-center study of PMMGCTs to date, following reports from Russia, 17 China, 18 and Peru. 19 We reported more cases with advanced-stage PMMGCTs.…”

Section: Discussionmentioning

confidence: 96%

Clinicopathological Features and Prognosis of Primary Mediastinal Malignant Germ Cell Tumors: A Retrospective Single-Institution Analysis

Zhang¹,

Chen²,

Liu³

et al. 2021

CMAR

View full text Add to dashboard Cite

“…In a multicenter study that enrolled 341 patients with PMGCTs from USA and Europe, Bokemeyer et al ( 2 , 4 ) reported the 5-year OS and PFS rates for mediastinal nonseminoma were 45 and 44%, respectively. A more recent study showed the 5-year OS rate was 46% for nonseminomatous patients ( 21 ). In the oriental population, Wang et al ( 22 ) reported that the 5-year OS and PFS rates of mediastinal nonseminomatous patients were 49.2 and 32.8%, respectively.…”

Section: Discussionmentioning

confidence: 99%

Clinical Characteristics and Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Single-Center Experience

Wang

Zhao

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Purpose: Primary mediastinal germ cell tumors (PMGCTs) are rare. The natural history and optimal treatment strategies still need to be defined. The aim of the study was to summarize the clinical characteristics, treatment outcomes, and prognostic factors of PMGCTs. Methods: Twenty-four patients with PMGCTs who were treated from December 2008 to January 2019 were evaluated retrospectively. The Kaplan–Meier method and Cox regression analysis were used to evaluate factors associated with prognosis. Results: The study population consisted of 23 male patients and 1 female patient. Five patients were diagnosed with seminoma and 19 patients were diagnosed with nonseminoma. The median follow-up time for all patients was 15.8 (3.9–114.5) months. The 5-year overall survival (OS) and progression free survival (PFS) rates for all patients were 65.2 and 44.3%. For nonseminoma and seminoma, the 5-year OS rates were 54.1 and 100% ( P = 0.093), respectively, and the 5-year PFS rates were 28.7 and 100%, respectively ( P = 0.044). In patients with nonseminoma, first-line radiotherapy indicated superior OS and PFS ( P = 0.037 and 0.027, respectively). The median survival time after recurrence was 4.3 months and the 1-year survival rate after recurrence was 23.4%. Conclusion: These results indicated that in PMGCTs, the prognosis of seminoma is superior to that of nonseminoma. Radiotherapy may be an essential treatment in patients with nonseminoma. Patients with relapse have unfavorable prognosis.

show abstract

Prognostic factors and efficacy of different chemotherapeutic regimens in patients with mediastinal nonseminomatous germ cell tumors

Abstract: CPOB and TBEP regimen were significantly associated with better outcome in pts with MNGCT. Age ≥ 24 years and size of the primary mediastinal tumor ≥ 19 cm were found as independent negative prognostic factors.

Cited by 12 publications

References 25 publications

Multimodality treatment outcome in patients with primary malignant mediastinal germ cell tumor in adults

Multimodality treatment outcome in patients with primary malignant mediastinal germ cell tumor in adults

Clinicopathological Features and Prognosis of Primary Mediastinal Malignant Germ Cell Tumors: A Retrospective Single-Institution Analysis

Clinical Characteristics and Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Single-Center Experience

Contact Info

Product

Resources

About